Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00016926 · ClinicalTrials.gov registry record · Phase 2
Capecitabine in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Phase 2 study, sponsored by Gynecologic Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00016926 is a Phase 2 study that has completed, run by Gynecologic Oncology Group.
The verdict
NCT00016926, a Phase 2 study, has completed, sponsored by Gynecologic Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of capecitabine in treating patients who have advanced, persistent, or recurrent cervical cancer.
Interventions
- DRUG capecitabine
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00016926
The ClinicalTrials.gov registry entry for NCT00016926 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Gynecologic Oncology Group, which has 154 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which capecitabine is the first listed.
NCT00016926 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00016926 about?
NCT00016926 is a clinical study titled "Capecitabine in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of capecitabine in treating patients who have advanced, persistent, or recurrent cervical cancer.
What is the current status of trial NCT00016926?
This trial is currently completed. It is a Phase 2 study. The study started on 2001-04.
What interventions are being tested in trial NCT00016926?
The interventions under investigation include: capecitabine (DRUG).
Who is sponsoring clinical trial NCT00016926?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.